You are on the TAC legacy website. Please visit our new website:

TAC complaint against MSD

warning: Creating default object from empty value in /usr/www/users/tacaor/public_site/community/modules/taxonomy/ on line 34.
Printer-friendly version

TAC complaint increases access to efavirenz: MSD finally agrees to grant licenses on reasonable terms

Acting on behalf of TAC, the AIDS Law Project (ALP) lodged a complaint with the Competition Commission of South Africa in late 2007 alleging that MSD (Pty) Ltd – the South African subsidiary of multinational drug company Merck – was unlawfully refusing to license the antiretroviral (ARV) medicine efavirenz (EFV) on reasonable terms. (“TAC complains to the Competition Commission about the anti-competitive conduct of the world's largest pharmaceutical company” at Today, TAC is pleased to announce that MSD is no longer acting in an anticompetitive way, paving the way for the market entry of a wide range of affordable EFV products.

Also read our updated fact sheet on the complaint.

Syndicate content